Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review.
Neoadjuvant therapy
colonic neoplasms
meta-analysis
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
ppublish
Résumé
The role of perioperative or neoadjuvant chemotherapy for locally advanced colon cancer is unclear. Emerging evidence such as the FOXTROT trial is challenging the conventional norm of upfront operation for these patients. However, these trials have yet to reach statistical significance. MEDLINE, Embase, Cochrane Library, China Knowledge Resource Integrated Database (CNKI) and ClinicalTrials.gov were searched. Randomized controlled trials (RCTs) and observational studies of patients with locally advanced colon cancer were included. The intervention arm was neoadjuvant chemotherapies while the comparator arm was adjuvant chemotherapies. Studies which reported outcomes of interests included overall survival, disease-free survival, R0 resection rate, perioperative complications and adverse effects of chemotherapy were chosen. We identified five eligible randomized trials and two observational studies, including 29,504 patients. Neoadjuvant therapies exhibited statistically significant improvement in overall survival [hazard ratio (HR) =0.76, 95% confidence interval (CI): 0.65-0.89, P=0.0005], and disease-free survival (HR =0.74, 95% CI: 0.58-0.95, P=0.02). R0 resection rate fell slightly short of significance [odds ratio (OR) =1.86, 95% CI: 0.95-3.62, P=0.07]. Risk of peri-operative complications did not differ between groups when examining abdominal infection [risk ratio (RR) =1.14, 95% CI: 0.59-2.18, P=0.70] and anastomotic leakage (RR =0.83, 95% CI: 0.53-1.31, P=0.42). No statistical differences in complications from chemotherapy were reported. This meta-analysis highlights the potential survival benefit of neoadjuvant chemotherapy compared to adjuvant chemotherapy for locally advanced colon cancer, without an increase in surgical morbidity. Neoadjuvant or perioperative approaches may be considered an alternative to upfront surgery followed by chemotherapy for locally advanced colon cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The role of perioperative or neoadjuvant chemotherapy for locally advanced colon cancer is unclear. Emerging evidence such as the FOXTROT trial is challenging the conventional norm of upfront operation for these patients. However, these trials have yet to reach statistical significance.
METHODS
METHODS
MEDLINE, Embase, Cochrane Library, China Knowledge Resource Integrated Database (CNKI) and ClinicalTrials.gov were searched. Randomized controlled trials (RCTs) and observational studies of patients with locally advanced colon cancer were included. The intervention arm was neoadjuvant chemotherapies while the comparator arm was adjuvant chemotherapies. Studies which reported outcomes of interests included overall survival, disease-free survival, R0 resection rate, perioperative complications and adverse effects of chemotherapy were chosen.
RESULTS
RESULTS
We identified five eligible randomized trials and two observational studies, including 29,504 patients. Neoadjuvant therapies exhibited statistically significant improvement in overall survival [hazard ratio (HR) =0.76, 95% confidence interval (CI): 0.65-0.89, P=0.0005], and disease-free survival (HR =0.74, 95% CI: 0.58-0.95, P=0.02). R0 resection rate fell slightly short of significance [odds ratio (OR) =1.86, 95% CI: 0.95-3.62, P=0.07]. Risk of peri-operative complications did not differ between groups when examining abdominal infection [risk ratio (RR) =1.14, 95% CI: 0.59-2.18, P=0.70] and anastomotic leakage (RR =0.83, 95% CI: 0.53-1.31, P=0.42). No statistical differences in complications from chemotherapy were reported.
CONCLUSIONS
CONCLUSIONS
This meta-analysis highlights the potential survival benefit of neoadjuvant chemotherapy compared to adjuvant chemotherapy for locally advanced colon cancer, without an increase in surgical morbidity. Neoadjuvant or perioperative approaches may be considered an alternative to upfront surgery followed by chemotherapy for locally advanced colon cancer.
Identifiants
pubmed: 33209481
doi: 10.21037/jgo-20-220
pii: jgo-11-05-847
pmc: PMC7657836
doi:
Types de publication
Journal Article
Langues
eng
Pagination
847-857Informations de copyright
2020 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-20-220). The authors have no conflicts of interest to declare.
Références
Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4
pubmed: 15570210
J Clin Oncol. 2019 Nov 20;37(33):3066-3068
pubmed: 31550189
Front Med (Lausanne). 2017 Apr 10;4:39
pubmed: 28443282
BMC Cancer. 2015 Jul 10;15:511
pubmed: 26156156
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Ann Surg. 2020 Mar;271(3):440-448
pubmed: 31318794
Syst Rev. 2015 Mar 06;4:23
pubmed: 25874584
Lancet Oncol. 2012 Nov;13(11):1152-60
pubmed: 23017669
Cancer. 2011 Jun 1;117(11):2364-70
pubmed: 24048783
J Gastrointest Surg. 2018 Feb;22(2):242-249
pubmed: 28933016
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Colorectal Dis. 2012 Dec;14(12):1457-66
pubmed: 22356246
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
BMJ. 2007 Jan 13;334(7584):94-6
pubmed: 17218716
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMJ. 2001 Jul 28;323(7306):224-8
pubmed: 11473921
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Acta Oncol. 2015 Nov;54(10):1747-53
pubmed: 25920359
Ann Surg. 2013 Dec;258(6):847-53
pubmed: 24169157
Br J Surg. 2006 Jul;93(7):872-8
pubmed: 16671066
BMJ. 2011 Aug 08;343:d2090
pubmed: 21824904
Ann Surg. 2020 Apr;271(4):637-645
pubmed: 31356278
Ann Transl Med. 2013 Jul;1(2):11
pubmed: 25332956
Acta Oncol. 2005;44(8):904-12
pubmed: 16332600
Dig Surg. 2020;37(4):292-301
pubmed: 31661689
Clin Transl Oncol. 2017 Mar;19(3):379-385
pubmed: 27496023
J Clin Oncol. 2006 Oct 1;24(28):4620-5
pubmed: 17008704
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
Colorectal Dis. 2015 Nov;17(11):943-53
pubmed: 25808496
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2008 Feb 10;26(5):778-85
pubmed: 18258986
Eur J Cancer. 2010 Apr;46(6):1049-55
pubmed: 20138505